Vorozole (Rivizor(TM)): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure

1998-03-09

Anti-Cancer Drugs , Volume 9 - Issue 1 p. 29- 35

Additional Metadata
Keywords	Aromatase, Breast cancer, Metastatic, Phase II, Postmenopausal, Vorozole
Persistent URL	doi.org/10.1097/00001813-199801000-00003, hdl.handle.net/1765/63578
Journal	Anti-Cancer Drugs
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Paridaens, R., Roy, J., Nooij, M. A., Klijn, J., Houston, S., Beex, L., … Piccart, M. (1998). Vorozole (Rivizor(TM)): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Anti-Cancer Drugs, 9(1), 29–35. doi:10.1097/00001813-199801000-00003

Publication